Irritable Bowel Syndrome (IBS) Treatment Market Size Worth $7.60 billion By 2032 | CAGR: 8.4%

The global irritable bowel syndrome (IBS) treatment market size is expected to reach USD 7.60 billion by 2032, according to a new study by Polaris Market Research. The report “Irritable Bowel Syndrome (IBS) Treatment Market Share, Size, Trends, Industry Analysis Report, By Medical Condition (IBS - Diarrhea, IBS - Constipation, IBS - Mixed) By Drug Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Irritable bowel syndrome is one of the most common functional gastrointestinal disorders. Which specific source of symptoms is unknown; however, it may be brought by an issue with the brain, neurological system, and stomach interaction.

Clinical trials are presently being conducted on a few promising items, which will speed up market growth further over the projection period; product sales are anticipated to increase considerably, primarily as a result of rising prevalence and the introduction of innovative medications for the treatment of irritable bowel syndrome (IBS).

The rise in stress levels brought on by a busy and demanding lifestyle and an increase in awareness campaigns for irritable bowel syndrome treatment and management speed up market expansion. The adoption of an unhealthy diet, as well as the rising incidence of gastrointestinal illnesses and disorders such as altered bowel habits and stomach discomfort, further impact the market.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market/request-for-sample

The intensity of symptoms, classified as mild, moderate, or severe, determines the course of treatment. Mild symptoms have little to no impact on one's quality of life. Severe symptoms, however, are more prevalent and powerful, and they must be handled. The condition is frequently correlated with diet, lifestyle, and stress variables, which may be managed by controlling stress levels, food, and exercise. Irritable bowel syndrome is mostly treated by relieving the patient of its symptoms which boosts the irritable bowel syndrome treatment market growth.

Irritable Bowel Syndrome (IBS) Treatment Market Report Highlights

• IBS - Diarrhea segment accounted for a maximum share in 2022. Increasing the number of patients in men and women is expected to boost the market.
• In addition, IBS- constipation held a significant revenue share due to increased demand for medications to treat both conditions.
• The drug type rifaximin segment is anticipated to have a high growth rate during the forecast period due to the rising prevalence of IBS and the development of advanced technological products.
• The Linaclotide drug type segment is expected to witness the highest CAGR over the anticipated period due to the development and production of the generic version of linaclotide.
• North America dominates the global irritable bowel syndrome industry due to increasing awareness of the condition and increasing the presence of competitors globally.
• The global key market players include Synthetic Biologics, Inc, Synergy Pharmaceuticals Inc, Bausch Health, Astellas Pharma Inc, Abbott Laboratories, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd, AstraZeneca plc and Novartis AG.

Polaris Market Research has segmented the Irritable Bowel Syndrome (IBS) Treatment market report based on type, application, shape, distribution channel, and region:

Irritable Bowel Syndrome (IBS) Treatment, Medical Condition Outlook (Revenue - USD Billion, 2019 - 2032)

• IBS - Diarrhea
• IBS - Constipation
• IBS - Mixed

Irritable Bowel Syndrome (IBS) Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Ramosetron Hydrochloride
• Linaclotide
• Rifaximin
• Eluxadoline
• Lubiprostone
• Others

Irritable Bowel Syndrome (IBS) Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Irritable Bowel Syndrome (IBS) Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa